Nasseri Atashani Fatemeh, Nasseri Elham, Zeinali Esmaeil, Zamani Roya, Salahshouri Aliakbar, Ghourchibeigi Mohsen, Heidari Parnaz, Koushan Ali, Naseri Atashani Narges, Heidari Behzad
Emergency Clinic, Shahriyar Hospital, Shahriyar, Karaj, Iran.
Department of Internal Medicine, Shahriyar Hospital, Karaj, Iran.
Caspian J Intern Med. 2022;13(Suppl 3):211-220. doi: 10.22088/cjim.13.0.211.
Despite advances in preventive measures, COVID -19 spread and mortality is continuing due to delay in timely diagnosis. This problem is partly dependent on variations in disease characteristics, distribution of risk factors particularly comorbidities and demographic characteristics of patients. This study aimed to determine the clinical presentation and associated factors of mortality in patients hospitalized with COVID -19 infection.
Patients were divided into survivor and deceased groups, and clinical and laboratory findings and factors associated with mortality between the two groups were compared by calculating odds ratio (OR) with 95% confidence interval (95% CI).
A total of 257 patients (female 45.1%) with a mean age of 59.8+15.7 years and a mean hospital stay of 4.89+3.57 days were studied. Diabetes, hypertension, cardiovascular disease and chronic renal disease (CRD) were found in 29.6%, 37.5%, 16.3% and 3.5% of all patients, respectively. Forty-one (16%) patients died. Factors such as age >50 years, coexisting CRD, serum creatinine > 2 mg/dl; SPO2 <70% lymphocytes < 20% during hospitalization were independently associated with mortality. The adjusted ORs (95% CI) were 10.08 (1.39-73); 4.51(1.15-17.61); 6 (1.14-31.5); 16.8(2.93-96.7); and 4.9(1.31-18.1), respectively. Most of the expected effective drugs were not associated with lower mortality.
These results indicate a high in-hospital mortality rate in COVID -19 patients. Some mortality factors occurring during hospitalization were reversible and could be prevented by timely diagnosis and appropriate treatment.
尽管预防措施有所进展，但由于及时诊断的延迟，新冠病毒疾病（COVID -19）仍在传播，死亡率仍在持续上升。这个问题部分取决于疾病特征的差异、风险因素（尤其是合并症）的分布以及患者的人口统计学特征。本研究旨在确定COVID -19感染住院患者的临床表现及死亡相关因素。
将患者分为存活组和死亡组，通过计算比值比（OR）及95%置信区间（95%CI）比较两组的临床和实验室检查结果以及与死亡相关的因素。
共研究了257例患者（女性占45.1%），平均年龄为59.8±15.7岁，平均住院时间为4.89±3.57天。所有患者中，糖尿病、高血压、心血管疾病和慢性肾病（CRD）的患病率分别为29.6%、37.5%、16.3%和3.5%。41例（16%）患者死亡。年龄>50岁、并存CRD、血清肌酐>2mg/dl、住院期间血氧饱和度<70%、淋巴细胞<20%等因素与死亡率独立相关。校正后的OR（95%CI）分别为10.08（1.39 - 73）；4.51（1.15 - 17.61）；6（1.14 - 31.5）；16.8（2.93 - 96.7）；以及4.9（1.31 - 18.1）。大多数预期有效的药物与较低死亡率无关。
这些结果表明COVID -19患者的院内死亡率较高。住院期间出现的一些死亡因素是可逆的，可通过及时诊断和适当治疗加以预防。
